Loading news...
Shineco (NASDAQ: SISI - Get Free Report) shares dropped 6.8% during mid-day trading on Tuesday. The stock traded as low as $0.2050 and last traded at $0.2050. Approximately 2,226 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 182,033 shares. The stock had previously closed at $0.22. Analysts
Shineco (NASDAQ: SISI - Get Free Report) shot up 51.6% during trading on Friday. The company traded as high as $0.3625 and last traded at $0.3625. 362 shares were traded during mid-day trading, a decline of 100% from the average session volume of 192,647 shares. The stock had previously closed at $0.2391. Analysts Set New
BEIJING , Sept. 12, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a developer and commercializer of induced pluripotent stem cell (iPSC) technology platforms, today announced two major strategic advances.
BEIJING , Sept. 10, 2025 /PRNewswire/ -- Shineco Inc. (NASDAQ: SISI) ("Shineco" or the "Company"), a leading developer of induced pluripotent stem cell (iPSC) technology platforms, today announced that its subsidiary, Fuzhou Meidashan Biotechnology Co., Ltd.
BEIJING , Aug. 27, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, has entered into a strategic cooperation agreement with Singapore-based BICC Pte Ltd to jointly promote the implementation and redemption of "on-chain cell assets" across multiple institutions and scenarios. This collaboration marks a new phase of "cross-enterprise redeemability" for cell assets on the blockchain, advancing the RWA ecosystem from "technical on-chain integration" to "real-world application.
BEIJING, Aug. 20, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a leading innovator in induced pluripotent stem cell (iPSC) technology, today announced the execution of a "Cellular Asset On-Chaining and Marketing Ecosystem Cooperation Agreement" with blockchain infrastructure provider Plus Me Limited. This partnership enables blockchain-based tokenization of biological cellular assets, facilitating seamless global transfers and auditable standardized custody, creating a novel 'Asset On-Chaining + Application Scenarios' model in cell therapy. The collaboration will redefine the global biological cell industry's commercial architecture. Under the agreement, Plus Me will deploy full lifecycle digital custody of Shineco's compliant mesenchymal stem cells (MSCs) on the Ethereum mainnet. Smart contracts will immutably secure asset ownership rights, issuing unique non-fungible digital identifiers (NFDIs) for each cellular asset to ensure traceability and compliance. Verifiable uniqueness and regulatory compliance are cryptographically enforced through on-chain hashing. Plus Me will issue ERC-1400/ERC-20 compliant security tokens, branded as "Cell Infusion Redemption Tokens." These utility tokens can be redeemed at Shineco-affiliated Cell Therapy Centers, with Tokens are programmatically burned upon redemption, enforcing scarcity and aligning long-term value for stakeholders. This RWA (Real-World Asset) tokenization framework addresses critical industry pain points: high user costs, unverifiable product provenance, and illiquid asset pools - converting biological assets into tradable digital instruments. To bolster the initiative, Shineco has secured a controlling 51% stake in Xi'an Dong'ao Health Management Co., Ltd., a specialist in cryogenic cell storage and clinical applications, provides the off-chain infrastructure critical to token redemption, as of August 18, 2025. This strategic buyout operationalizes the tokenization initiative, providing off-chain infrastructure for token redemption. Combined with previously acquired Singapore firm Infiniclone, Shineco now controls a global storage and infusion network ensuring on-chain<>off-chain asset settlement. The parties will co-build an open-cell industry ecosystem: Plus Me provides tokenization SaaS to third parties, while Shineco opens its physical custody network. Shineco maintains off-chain biological QA, with Plus Me ensuring on-chain regulatory compliance - creating cross-jurisdictional synergy with entities like Singapore's ACTRIS. This tokenized ecosystem transforms Shineco from a sole service provider into a global infrastructure provider for the cell economy, positioning the ecosystem for rapid revenue scalability. Shineco's asset tokenization protocol aligns with the industry's shift from clinical trials to commercial scalability. "This marks the birth of a decentralized biotech economy-where every cell becomes a liquid, programmable asset, unlocking unprecedented value for medicine and investors alike," said Jennifer Zhan, CEO of Shineco. "Token holders gain governance rights, including future DAO voting to enhance global ecosystem development in cell therapy-fundamentally transforming traditional marketing paradigms." About Plus Me Limited Plus Me provides enterprise-grade blockchain middleware, offering end-to-end solutions for digital asset compliance, tokenomics architecture, and cross-border liquidity deployment. The firm architects Web3 economic models with global exchange partnerships. About Xi'an Dong'ao Health Management Co., Ltd. Xi'an Dong'ao Health provides GMP-compliant biostorage and clinical cell applications, delivering integrated health management via "Prevention-Intervention-Maintenance" protocols. About Shineco, Inc. Shineco, Inc. ("Shineco" or the "Company") aims to "focus on healthy living and improve the quality of life" by providing safe, efficient and high-quality health and medical products and services to society. The Company's core business encompasses induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products. For more information about Shineco, please visit www.biosisi.com/. Forward-Looking Statements This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements can be identified by words such as "may," "will," "should," "could," "intend," "expect," "plan," "budget," "anticipate," "believe," "estimate," "forecast," "potential," "continue," "evaluate" or similar words. Forward-looking statements should not be relied upon as they are neither historical facts nor guarantees of future performance. Rather, they are based solely on our current beliefs, expectations and assumptions about future business, future plans and strategies, forecasts, expected events and trends, economics, and other future conditions. Examples of forward-looking statements include, our innovation and market position in our products and services, our competitive advantages, and our expectation that the 5-minute cardiac test will be one of the leading products in this field to meet the need for test results immediately upon intake. Please do not rely on any forward-looking statements. Actual results may differ materially from those indicated in historical results or forward-looking statements due to various factors, including, but not limited to, the Company's ability to raise additional capital, its ability to maintain and grow its business, the variability of its results of operations, its ability to maintain and enhance its brand, its ability to develop and introduce new products and services, its ability to obtain all necessary regulatory approvals in the jurisdictions in which it intends to market and sell its products, companies to be acquired, successful integration of technology and assets into its portfolio of products and services, marketing and other business development initiatives, industry competition, general government regulations, economic conditions, impact of the COVID-19 pandemic, reliance on key personnel, attracting, hiring and retaining personnel with the technical skills and experience required to meet customer requirements and protecting its intellectual property. Shineco encourages you to review these and other factors that may affect its future performance in its filings with the Securities and Exchange Commission. The forward-looking statements in this press release are based only on information currently available to us and are made only as of the date of this press release, and Shineco undertakes no obligation to update any forward-looking statements, except as required by applicable rules and regulations. For media inquiries or partnership opportunities, contact: Shineco, Inc. Mobile: +86-010-68130220 SOURCE Shineco,Inc.
BEIJING , Aug. 13, 2025 /PRNewswire/ -- Shineco Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, today announced the establishment of a Biological Cell Digital Business Division (the "Division"), and the appointment of Mr. Lin Hongguang as General Manager, to advance the integration of its biological cell assets and blockchain technology.
Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price BEIJING, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (Nasdaq:SISI) ("Shineco" or the "Company"), a provider of innovative diagnostic medical products and related medical devices, today announced that the Company's Board of Directors has approved a 50:1 reverse stock split of the Company's issued and outstanding common stock, par value $0.001 per share (the "Common Stock") to be effective 12:01 a.m., Eastern Time, on August 11, 2025.
The Acquisition is Expected to Create Immediate Synergies with the Company's Existing Medical Device Business BEIJING, March 25, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on March 20, 2025, Shineco Life Science Group Hong Kong Co., Limited (“Shineco Life Science”), a subsidiary of the Company, entered into a Stock Purchase Agreement (“SPA”) with Yi Yang (the “Seller”), for 75% of an equity interest in FuWang (HK) International Company Limited (“FuWang Company”). The Seller is the current and only shareholder of FuWang Company, which specializes in the R&D, manufacturing, and commercialization of medical devices.
NEW YORK , Aug. 9, 2024 /PRNewswire/ -- Future Fintech Group Inc. (NASDAQ: FTFT), (hereinafter referred to as "Future FinTech", "FTFT" or the "Company"), a comprehensive financial and digital technology service provider, today announced that its Board of Directors (the "Board") approved the appointment of Mr. Hu Li as Chief Executive Officer ("CEO"), President and a member of the Board of the Company, effective August 5, 2024.
Beijing, July 15, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced the closing of its underwritten public offering of 1,869,160 shares of its common stock at a public offering price of $1.07 per share of common stock, for aggregate gross proceeds of approximately $2 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 280,374 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any.
Shineco (NASDAQ: SISI ) stock is falling hard on Friday after the agricultural produce company announced the pricing of a public offering for its shares. This public offering has Shineco selling 1,869,160 shares of SISI stock for $1.07 each.
Beijing, July 12, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced the pricing of its underwritten public offering of 1,869,160 shares of its common stock at a public offering price of $1.07 per share of common stock, for aggregate gross proceeds of approximately $2 million, prior to deducting underwriting discounts and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 280,374 shares of common stock at the public offering price per share, less the underwriting discounts to cover over-allotments, if any. The offering is expected to close on July 15, 2024, subject to satisfaction of customary closing conditions.
Beijing, July 11, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”) (NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, today announced it has commenced an underwritten public offering of shares of its common stock and pre-funded warrants to purchase its shares of common stock. All of the shares of common stock and pre-funded warrants and the shares of common stock underlying the pre-funded warrants are being offered by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
BEIJING, June 27, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices, announced today that on June 5, 2024, the Company received a formal notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). The notice indicated that as a result of the closing bid price of the Company's common stock having been at least $1.00 per share for the period of 10 consecutive business days, from May 20, 2024 through June 4, 2024, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and advised that this matter is now closed.
BEIJING, June 24, 2024 (GLOBE NEWSWIRE) -- Shineco, Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a provider of innovative diagnostic medical products and related medical devices, announced today that on June 20, 2024, the Company entered into a Securities Purchase Agreement (the “SPA”) with certain non-U.S. investors (each individually, a “Purchaser,” and collectively, the “Purchasers”). Pursuant to the SPA, the Company will issue up to 1,400,000 shares of its common stock (the “Shares”) to the Purchasers in a private placement financing transaction (the “Offering”) at an offering price of $5.00 per share. The gross proceeds of the Offering are expected to be approximately $7,000,000, before the deduction of customary expenses. The Purchasers are a former related party of the Company, who agreed to purchase 1,000,000 shares of common stock, a management member of the Company, who agreed to purchase 200,000 shares of common stock, and an individual investor who agreed to purchase 200,000 shares of common stock. The Offering is expected to close, and the Shares are expected to be issued, on or about July 31, 2024.
BEIJING, June 20, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDA: SISI), a producer of innovative diagnostic medical products and related medical devices announced today that on June 18, 2024, it entered into an Investment Letter of Intent (the “Investment LOI”) with Beijing Oriental Meitong Technology Co., Ltd. (“Meitong Technology”) whereby Shineco intends to invest $20 million in Meitong Technology in exchange for 80% of Meitong Technology's shares. The Company believes that the acquisition of equity in Meitong Technology will add to the Company's core competencies and result in operating synergies that will enhance the Company's value proposition.
Beijing, June 17, 2024 (GLOBE NEWSWIRE) -- Shineco Inc. (“Shineco” or the “Company”; NASDAQ: SISI), a producer of innovative diagnostic medical products and related medical devices announced today that on June 14, 2024, its 51% owned subsidiary, Shangkang Life Science and Technology (Jiangsu) Co., Ltd. (“Shangkang Life Science”) entered into a Strategic Cooperation Framework Agreement (“the Agreement”) with Turing Video (Shenzhen) Co., Ltd (“Turing Video”) to jointly develop a series of smart medical products and introduce their biotechnology and other innovative health solutions to the healthcare market.
Shares of Virios Therapeutics, Inc. VIRI fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share. Virios Therapeutics shares dipped 47.6% to $0.1850 on Monday. Here are some other stocks moving in today’s mid-day session. MultiMetaVerse Holdings Limited MMV shares jumped 224% to $2.01. MultiMetaVerse Holdings signed a non-binding term sheet to acquire 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries. GT Biopharma, Inc. GTBP rose 146% to $7.64. GT Biopharma, last week, posted a narrower-than-expected quarterly loss. Tantech Holdings Ltd TANH jumped 89.8% to $1.2501. Faraday Future Intelligent Electric Inc. FFIE shares gained 62.1% to $1.6701. Faraday Future Intelligent Electric is scheduled to report its fourth quarter and full year 2023 results after the closing bell on Tuesday, May 28. CN Energy Group. Inc. CNEY surged 58% to $1.0501. Scorpius Holdings, Inc. SCPX gained 57.8% to $0.1635. Scorpius, last week, announced closing of public offering. NKGen Biotech, Inc. NKGN rose 46% to $1.6250 after the company’s SNK01 NK Cell Therapy was cleared to begin a Phase 2 trial in Alzheimer’s disease. Bruush Oral Care Inc. BRSH jumped 41% to $0.1658. Rekor Systems, Inc. REKR gained 36% to $1.80 after the company announced a partnership with MS2. MIRA Pharmaceuticals, Inc. MIRA gained 34.3% to $0.8866 after the company said it has advanced new preclinical studies using Ketamir-2 towards clinical development. Scilex Holding Company SCLX gained 34% to $1.21. Hims & Hers Health, Inc. HIMS rose 30.5% to $19.01 after the company announced the addition of GLP-1 injections to its weight loss portfolio. BYND Cannasoft Enterprises Inc. BCAN surged 29.5% to $1.4250. Cheetah Mobile Inc. CMCM gained 24.3% to $5.70. Concord Medical Services Holdings Limited CCM jumped 23% to $0.6188. Wix.com Ltd. WIX rose 21.6% to $164.94 as the company posted upbeat results for its first quarter and raised its 2024 forecast on Monday. Sintx Technologies, Inc. SINT shares rose 21.1% to $0.1029 after dipping over 39% on Friday. Sutro Biopharma, Inc. STRO climbed 17.6% to $4.7150. PTC Therapeutics, Inc. PTCT jumped 17.2% to $38.78 after the company announced the European Commission has returned the Translarna opinion to the CHMP for re-evaluation. Cue Health Inc. HLTH gained 17.1% to $0.1128 after dipping around 18% on Friday. Cue Health, last week, announced that it voluntarily and temporarily paused sales and distribution of its EUA COVID-19 Test Cartridge. NextDecade Corporation NEXT climbed 16% to $8.10 after ADNOC announced it secured an equity position and LNG offtake agreement in NextDecade’s Rio Grande LNG project. NuScale Power Corporation SMR rose 15.5% to $7.29. VinFast Auto Ltd. VFS gained 15% to $5.61. Crown ElectroKinetics Corp. CRKN shares rose 14.8% to $0.1964 after falling around 29% on Friday. Tellurian Inc. TELL gained 14% to $0.5870. Shineco, Inc. SISI shares climbed 10.2% to $1.09 after jumping 19% on Friday. Shineco recently announced that its subsidiaries Fuzhou Medashan Biotechnology and Kaifeng Yixi Biotechnology invented a new natural active water-soluble product. Independent Bank Group, Inc. IBTX gained 8.5% to $47.69 after SouthState announced it will acquire the company. Doximity, Inc. DOCS surged 5.1% to $29.46. Akoustis Technologies, Inc. AKTS fell 53.8% to $0.1647 after Qorvo won a jury verdict against the company in a trade secret misappropriation and patent infringement case. Cheetah Net Supply Chain Service Inc. CTNT declined 48% to $5.61. FLJ Group Limited FLJ shares fell 44.5% to $0.86 after surging 224% on Friday. Jaguar Health, Inc JAGX fell 39.8% to $0.1557 after the company announced a 1-for-60 reverse stock split. Fangdd Network Group Ltd. DUO declined 38% to $1.04. Jeffs’ Brands Ltd JFBR shares declined 35.8% to $0.4189 after jumping 109% on Friday. DermTech, Inc. DMTK fell 33.8% to $0.3302. CervoMed Inc. CRVO declined 25.3% to $17.99. CervoMed named William Elder as Chief Financial Officer, effective June 1. Barnes & Noble Education, Inc. BNED dipped 22.6% to $0.3482. Akanda Corp. AKAN shares fell 22.3% to $0.1339 following a 30% surge on Friday. iPower Inc. IPW shares fell 20.8% to $2.29 after jumping 98% on Friday. iPower, last week, reported better-than-expected third-quarter financial results. Nature’s Miracle Holding Inc. NMHI declined 19.9% to $0.5396. Nature’s Miracle mutually agreed to terminate plan to merge with Agrify Corp. Li Auto Inc. LI fell 12.6% to $21.74 after the company reported worse-than-expected first-quarter results and issued second-quarter guidance. GameStop Corp. GME declined 10% to $19.99. Oklo Inc. OKLO fell 8.6% to $8.23. IGM Biosciences, Inc. IGMS declined 8.2% to $8.46. Cemtrex, Inc. CETX shares fell 7.6% to $0.45 after climbing 49% on Friday. Cemtrex, last week, posted a wider quarterly loss. The Beauty Health Company SKIN declined 5.8% to $2.58. Inovio Pharmaceuticals, Inc. INO fell 5.6% to $11.33. ATRenew Inc. RERE shares fell 4.3% to $2.71 after reporting weak quarterly earnings. Now Read This: How To Earn $500 A Month From Lowe’s Stock Ahead Of Q1 Earnings Report © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
BEIJING , May 1, 2024 /PRNewswire/ -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd.